Novavax COVID-19 vaccine shows over 90% efficacy in the U.S. late-stage trial

Novavax Inc (NASDAQ: NVAX) said on Monday its candidate COVID-19 vaccine showed 93% efficacy in its U.S. late-stage trial. The results of the clinical trial also confirmed the vaccine to be effective against a range of predominant Coronavirus variants. Novavax’s head of R&D, Dr Gregory Glenn, said: “Practically speaking, it’s very important that the vaccine […]